An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

Ovarian cancer is a leading cause of death from gynecologic malignancies. Treatment for advanced-stage disease remains limited and, to date, targeted therapies have been incompletely explored. By systematically suppressing each human tyrosine kinase in ovarian cancer cell lines by RNAi, we found that an autocrine signal-transducing loop involving NRG1 and activated ErbB3 operates in a subset of primary ovarian cancers and ovarian cancer cell lines. Perturbation of this circuit with ErbB3-directed RNAi decreased cell growth in three-dimensional culture and resulted in decreased disease progression and prolonged survival in a xenograft mouse model of ovarian cancer. Furthermore, a monoclonal ErbB3-directed antibody (MM-121) also significantly inhibited tumor growth in vivo. These findings identify ErbB3 as a potential therapeutic target in ovarian cancer.

[1]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[2]  H. Kim,et al.  Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. , 1994, The Journal of biological chemistry.

[3]  H. Land,et al.  A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells. , 1990, Nucleic acids research.

[4]  A. Oza,et al.  Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Thigpen.  Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer , 2011 .

[6]  A. Joe,et al.  Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.

[7]  H. Burris,et al.  A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. , 2007, Gynecologic oncology.

[8]  C. Bucana,et al.  Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. , 2004, Gynecologic oncology.

[9]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  K. Darcy,et al.  Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Jie Zhang,et al.  SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. , 2007, The American journal of pathology.

[12]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[13]  W. Wong,et al.  Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. , 2004, Cancer genetics and cytogenetics.

[14]  A. Sood,et al.  EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma , 2004, Clinical Cancer Research.

[15]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[16]  M. Sliwkowski,et al.  A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. , 2008, Cancer research.

[17]  A. Ullrich,et al.  Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic , 1991, Journal of Clinical Immunology.

[18]  J. Contessa,et al.  Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation , 2005, Breast Cancer Research and Treatment.

[19]  Anne E Carpenter,et al.  A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen , 2006, Cell.

[20]  Alice T. Loo,et al.  PTEN-deficient cancers depend on PIK3CB , 2008, Proceedings of the National Academy of Sciences.

[21]  A. Ullrich,et al.  ErbB-3 predicts survival in ovarian cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  N. Hanna,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .

[23]  J. Smyth,et al.  Neuregulin expression, function, and signaling in human ovarian cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  A. Baron,et al.  Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. , 2008, Biochimica et biophysica acta.

[25]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[26]  Martin Fussenegger,et al.  Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. , 2003, Biotechnology and bioengineering.

[27]  V. Ogryzko,et al.  Immunoaffinity purification of mammalian protein complexes. , 2003, Methods in enzymology.

[28]  David L Rimm,et al.  Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer , 2005, Clinical Cancer Research.

[29]  E. Wilander,et al.  Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. , 1993, Cancer research.

[30]  Andrew L Kung,et al.  A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[32]  V. Grantcharova,et al.  Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.

[33]  Molly Brewer,et al.  Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  L. Cantley,et al.  ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor , 1994, Molecular and cellular biology.

[35]  A. Jazaeri,et al.  Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics , 2007, Expert opinion on pharmacotherapy.

[36]  T. Hunter.  The role of tyrosine phosphorylation in cell growth and disease. , 1998, Harvey lectures.

[37]  Sreenath V. Sharma,et al.  Oncogene addiction: setting the stage for molecularly targeted cancer therapy. , 2007, Genes & development.

[38]  J. Weatherill,et al.  c-erbB-3 protein expression in ovarian tumours. , 1995, British Journal of Cancer.

[39]  T. Hunter,et al.  Meeting at Mitosis: Cell Cycle-Specific Regulation of c-Src by RPTPα , 2002, Science's STKE.

[40]  T. Miyake,et al.  c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function , 2007, Oncogene.

[41]  H. Phillips,et al.  c‐erbb growth‐factor‐receptor proteins in ovarian tumours , 1995, International journal of cancer.

[42]  R. Drapkin,et al.  Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. , 2010, Neoplasia.

[43]  L. Anderson,et al.  The ERBB3 receptor in cancer and cancer gene therapy , 2008, Cancer Gene Therapy.

[44]  Z. Hall.  Cancer , 1906, The Hospital.